Affiliation:
1. FSBSI “Mental Health Research Centre”
Abstract
Background: сognitive impairment and late depression, along with dementia, are the most common mental disorders in elderly and senile patients. Currently, more and more attention is being paid to preventive therapeutic approaches in the treatment of these conditions and to the study of drugs with multimodal neuroprotective and neurotrophic properties that contribute to the strengthening of the so-called endogenous system of protection and recovery of the brain, which is a kind of barrier to the incipient neurodegeneration. Objective: to present a review of domestic and foreign modern studies devoted to the study of the multimodal effects of the drug cerebrolysin, which has neurotrophin-like properties, and the results of its use in the treatment of cognitive disorders that do not reach the degree of dementia, as well as late depression. Material and methods: using the keywords “late age, mild cognitive disorders, depression, MCI syndrome, therapy, cerebrolysin”, we searched for scientifi c articles in the MEDLINE and PubMed databases for the period 2000–2020. Conclusion: the data presented in the review showed that cerebrolysin, acting as a multi-target drug, affects multiple molecular mechanisms of the pathogenesis of pre-dementia cognitive disorders and late-age depression. The drug detects a neurotrophin-like effect, improves the processes of neuroplasticity and can help enhance the protection and restoration of the brain under various pathological infl uences. Neurobiological studies and the results of a pilot prospective study indicate the preventive potential of cerebrolysin in preventing the development or slowing the progression of the neurodegenerative process of Alzheimer’s type. In the studies presented in the review, the ability of cerebrolysin to increase the effectiveness of modern antidepressant therapy (with second-generation drugs) in the elderly has been shown, presumably by potentiating the therapeutic effect of antidepressants or by improving their tolerability, which makes it possible to safely use higher doses of antidepressants in the elderly and senile patients.
Publisher
Medical Informational Agency Publishers
Reference46 articles.
1. Gavrilova SI, Kolykhalov IV, Fedorova IaB, Selezneva ND, Kalyn IaB, Roshchina IF, Odinak MM, Emelin AIu, Kashin AV, Gustov AV, Antipenko EA, Korshunova IuA, Davydova TA, Messler G. Possibilities of preventive treatment of Alzheimer’s disease: results of the 3- year open prospective comparative study on effi cacy and safety of the course therapy with cerebrolysin and cavinton in elderly patients with the syndrome of mild cognitive impairment. Zhurnal Nevrologii i Psikhiatrii iImeni SS Korsakova. 2010; 110(1):62–69. (In Russ.).
2. Reisberg B, Ferris SH, de Leon MJ, Crook T. The global deterioration scale (GDS). An instrument for the assessment of primary degenerative dementia (PDD). Am. J. Psychiatry. 1982; 139:1136–1139. doi: 10.1176/ ajp.139.9.1136
3. Morris JC. The Clinical dementia rating (CDR). Current version and scoring rules. Neurology. 1993; 43:2412– 2414. doi: 10.1212/wnl.43.11.2412-a
4. Korovaytseva GI, Shcherbatykh TV, Selezneva ND, Gavrilova SI, Golimbet VE, Voskresenskaya NI, Rogaev EI. Genetic association between alleles of the apolipoprotein E (AOE) gene and various forms of Alzheimer’s disease. Genetics. 2001; 37(4):529–533. (In Russ.). DOI.org/10.1023/A:1016610727938
5. Sharma HS, Sharma A, Mossler H, Muresanu DF. Neuroprotective effects of cerebrolysin, a combination of different active fragments of neurotrophic factors and peptides on the whole body hyperthermiainduced neurotoxicity: modulatory roles of co-morbidity factors and nanoparticle intoxication. Int. Rev. Neurobiol. 2012; 102:249–276. doi: 10.1016/B978-0-12-386986-9.00010-7
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献